KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Two years efficacy and safety outcomes of using allogeneic, pooled mesenchymal stromal cells for osteoarthritis of knee in a double-blind randomized placebo-controlled phase 3 study.

Pawan Kumar Gupta, Sunil Maheshwari, Joe Joseph Cherian, Vijay Goni, Arun Kumar Sharma, Sujit Kumar Tripathy, Keerthi Talari, Vivek Pandey, Parag Kantilal Sancheti, Saurabh Singh, Syamasis Bandyopadhyay, Naresh Shetty, Surendra Umesh Kamath, Purohit Sharad Prahaldbhai, Jijy Abraham, Suresh Kannan, Nikhil N Verma, Uday Kumar

Osteoarthr Cartil Open 8(1) 100723

PMID41536418
PMCIDPMC12796108
DOI10.1016/j.ocarto.2025.100723
发表日期2026-01-15
摘要

摘要

OBJECTIVE: The aim of this study was to assess whether allogeneic cultured, pooled, bone marrow derived mesenchymal stromal cells (BMMSCs), has potential to impact progression of osteoarthritis (OA). METHOD: Randomized, double blind, multicentric, placebo-controlled trial to assess efficacy and safety of BMMSCs in Grade 2 and 3 OA of knee. 146 patients were randomized, 73 patients each received either BMMSCs (25 million cells) or placebo followed by 20 mg HA. The primary end point was evaluation of WOMAC Composite Index and secondary end points were WOMAC sub-scores, VAS, magnetic resonance (MR) assessment (T2 mapping and cartilage volume). RESULTS: 58 patients from BMMSC arm and 60 patients from placebo arm completed 24 months follow-up. At 24 months follow up, WOMAC composite index and WOMAC sub scores showed significant improvements in cell arm as compared to placebo (p < 0.0001); T2 mapping showed there is no worsening of the cartilage in the medial femoral tibial compartment in BMMSC arm whereas placebo arm shows gradual worsening (p < 0.0001). Cartilage volume increased in BMMSC arm. At Day 90 & 730, Urinary C - terminal cross linked telopeptide of type II collagen significantly decreased in the cell arm and increased in the placebo arm (p-value<0.0001). 5 AEs were possibly related to the study drug and were local site administration effects. By 24 months follow-up, 4 patients in the placebo group underwent TKR versus 1 patient in the BMMSC arm. CONCLUSIONS: This study demonstrates that BMMSC's is safe and effective for the treatment of grade 2 & 3 OA of knee. CTRI REGISTRATION: CTRI/2018/09/015785 [Registered on: September 20, 2018].

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。